1Sibley SD, Palmer JP, Hirsch IB, et al. Visceral obesity, hepatic lipase activity, and dyslipidemia in type 1 diabetes [J]. J Clin Endocrinol Metab, 2002, 88: 3379- 3384.
2Dhahbi JM, Mote PL, Cao SX, et al. Hepatic gene expression profiling of streptozotocin-induced diabetes [J ]. Diabetes Technol Ther, 2003, 5:411 -420.
3周永兴,主编．现代肝硬化的诊断治疗[M]．北京：人民军医出版社,2002．134-135．
4Perseghin G, Mazzaferro V, Sereni LP, et al. Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation [J].Hepatology, 2000, 31: 694- 703.
5Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis [J]. JAMA,2003, 289: 3000- 3004.
6Iozzo P, Hallsten K, Oikonen V, et al. Insulin-mediated hepatic glucose uptake is impaired in type 2 diabetes: evidence for a relationship with glycemic control [J]. J Clin Endocrino Metab,2003, 88.. 2055- 2060.
7Wiegman CH, Bandsma RH, Ouwens M, et al. Hepatic VLDL production in ob/ob mice is not stimulated by massive de novo lipogenesis but is less sensitive to the suppressive effects of insulin[J]. Diabetes, 2003, 52:1081 - 1089.
8Angelico F, Del Ben M, Conti R, et al. Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases[J]. J Gastroenterol Hepatol, 2003, 18:588 - 594.
10Vogl T J,Zangos S,Balzer J O,et al.Transarterial chemoem- bolization of liver metastases: Fortschritte auf dem Gebiete (4):659-660 indication, technique, results. der Rontgenstrahlen, 2014,22.
